However, two ELISpot ratios (RD1/PPD, RD1/antiCD3) and a FC (CD8+CD25+CD134+ [MTB300-nil] T-cells) assay showed an upward trend in progressive MAC lung disease. Here, CD8A is linked to lung disorder.